Intervacc Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Intervacc de winst en omzet met respectievelijk 26.6% en 104.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 26.3% per jaar.

Belangrijke informatie

26.6%

Groei van de winst

26.3%

Groei van de winst per aandeel

Biotechs winstgroei	45.7%
Inkomstengroei	104.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Recent updates

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Dec 15

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

Jun 01

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

May 17

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

Feb 28

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Feb 01

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Dec 10

Winst- en omzetgroeiprognoses

OM:IVACC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	113	-38	-40	-38	1
12/31/2025	35	-64	-67	-65	1
12/31/2024	13	-74	-59	-58	1
9/30/2024	9	-77	-49	-49	N/A
6/30/2024	10	-103	-50	-49	N/A
3/31/2024	9	-103	-54	-52	N/A
12/31/2023	8	-103	-48	-46	N/A
9/30/2023	10	-106	-57	-55	N/A
6/30/2023	10	-73	-60	-57	N/A
3/31/2023	12	-71	-65	-62	N/A
12/31/2022	12	-64	-76	-70	N/A
9/30/2022	10	-50	-70	-57	N/A
6/30/2022	10	-44	-65	-47	N/A
3/31/2022	9	-34	-55	-33	N/A
12/31/2021	9	-29	-49	-25	N/A
9/30/2021	9	-28	-43	-24	N/A
6/30/2021	8	-26	-38	-22	N/A
3/31/2021	7	-26	-36	-23	N/A
12/31/2020	7	-26	-31	-20	N/A
9/30/2020	7	-26	-35	-18	N/A
6/30/2020	8	-26	-39	-15	N/A
3/31/2020	9	-29	-45	-10	N/A
12/31/2019	14	-28	-42	-3	N/A
9/30/2019	16	-27	-40	0	N/A
6/30/2019	26	-26	-29	6	N/A
3/31/2019	41	-29	-28	0	N/A
12/31/2018	38	-27	-28	-4	N/A
9/30/2018	38	-27	-32	-12	N/A
6/30/2018	38	-24	N/A	-17	N/A
3/31/2018	43	-16	N/A	-28	N/A
12/31/2017	50	-13	N/A	-19	N/A
9/30/2017	52	-11	N/A	-17	N/A
6/30/2017	56	-9	N/A	-23	N/A
3/31/2017	63	-6	N/A	-1	N/A
12/31/2016	58	-7	N/A	-4	N/A
12/31/2015	65	0	N/A	-19	N/A
12/31/2014	80	9	N/A	N/A	N/A
12/31/2013	1	-2	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IVACC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IVACC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IVACC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IVACC ( 104.9% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.1% per jaar).

Hoge groei-inkomsten: De omzet van IVACC ( 104.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IVACC naar verwachting over 3 jaar hoog zal zijn

Intervacc Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Recent updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

New major risk - Share price stability

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

We're Not Worried About Intervacc's (STO:IVACC) Cash Burn

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Independent Director recently sold kr29m worth of stock

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

New 90-day high: kr76.60

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)

Revenue and earnings miss expectations

Intervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021

Intervacc AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day high: kr54.80

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for Strangvac

Third quarter 2020 earnings released: kr0.13 loss per share

Revenue and earnings miss expectations